Myelofibrosis Mf clinical trials

Explore recruiting myelofibrosis mf clinical trials.

Recruiting myelofibrosis mf studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myelofibrosis Mf trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis.

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.

Greece, Italy, Germany, Spain, France, Bulgaria +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Germany, Czechia, Romania, Ireland, Austria, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination with an Approved JAK inhibitor in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)

Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

I3X-MC-JHTB: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Spain, Germany, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor

Denmark, Austria, Portugal, Poland, Germany, Spain +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Myelofibrosis Mf trials by city

Myelofibrosis Mf in Toronto Myelofibrosis Mf in Vancouver Myelofibrosis Mf in Montreal Myelofibrosis Mf in Calgary Myelofibrosis Mf in Edmonton Myelofibrosis Mf in Ottawa Myelofibrosis Mf in Winnipeg Myelofibrosis Mf in Quebec City Myelofibrosis Mf in Hamilton Myelofibrosis Mf in Kitchener Myelofibrosis Mf in London Myelofibrosis Mf in Halifax Myelofibrosis Mf in New York Myelofibrosis Mf in Los Angeles Myelofibrosis Mf in Chicago Myelofibrosis Mf in Houston

Myelofibrosis Mf clinical trials

Recruiting myelofibrosis mf studies right now

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Medium to High Risk Myelofibrosis

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

Also recruiting in Europe

A phase 2, randomized, open-label, multicenter study to evaluate safety and efficacy of single agent selinexor versus treatment of physician’s choice in patients with previously treated myelofibrosis.

A Phase 3b, open-label, single-arm, rollover study to evaluate long-term safety in subjects who have participated in other luspatercept (ACE-536, also known as BMS 986346) clinical trials.

A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination with an Approved JAK inhibitor in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)

I3X-MC-JHTB: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK)-Inhibitor

Myelofibrosis Mf trials by city

Other conditions